LRRC15/LIB hFc Chimera, Human
LRRC15/LIB HFc Chimera, Human

Immobilized LRRC15/LIB hFc Chimera, Human, hFc Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-LRRC15 Antibody, hFc Tag with the EC50 of 18.0ng/ml determined by ELISA.

LRRC15/LIB HFc Chimera, Human

The purity of LRRC15/LIB hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

LRRC15/LIB HFc Chimera, Human

LRRC15/LIB hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

LRRC15/LIB hFc Chimera, Human

The chimeric protein binds in vitro and in vivo to a specific element upstream of LRRC15, leading to dramatic transcriptional activation. LRRC15 encodes a leucine-rich transmembrane protein, present at the leading edge of migrating cells, the expression of which in normal tissues is restricted to the invasive cytotrophoblast layer of the placenta; small interfering (siRNA)-mediated suppression of LRRC15 expression in breast cancer cells leads to abrogation of invasiveness in vitro.
Z05613
¥72,752.00

Ask us a question
Product Introduction
Species Human
Protein Construction
LRRC15/LIB (Tyr22-Gly538)_x000D_
Accession # Q8TF66-1		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 84.54 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 90-120 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • LRRC15/LIB HFc Chimera, Human
    • LRRC15/LIB HFc Chimera, Human

    Immobilized LRRC15/LIB hFc Chimera, Human, hFc Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-LRRC15 Antibody, hFc Tag with the EC50 of 18.0ng/ml determined by ELISA.

  • LRRC15/LIB HFc Chimera, Human
    • LRRC15/LIB HFc Chimera, Human

    The purity of LRRC15/LIB hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

  • LRRC15/LIB HFc Chimera, Human
    • LRRC15/LIB HFc Chimera, Human

    LRRC15/LIB hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background The chimeric protein binds in vitro and in vivo to a specific element upstream of LRRC15, leading to dramatic transcriptional activation. LRRC15 encodes a leucine-rich transmembrane protein, present at the leading edge of migrating cells, the expression of which in normal tissues is restricted to the invasive cytotrophoblast layer of the placenta; small interfering (siRNA)-mediated suppression of LRRC15 expression in breast cancer cells leads to abrogation of invasiveness in vitro.
Synonyms LIB; LRRC15

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.